25-27 August, Los Angeles
![]() |
![]() |
![]() |
![]() |
P-03 | A first-in-human phase 1 study of oral LOXO-338, a ive BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) | NAIMAH BOLAJI | ![]() |
![]() |
|||
P-04 | Successful Ex-plantation of Left Ventricular Assist Device After Cardiac Recovery with Daratumumab Therapy in a Patient with End Stage Heart Failure due to Immunoglobulin Light-chain (AL) Amyloidosis | Daryl Tan | ![]() |
![]() |
|||
P-06 | Real World Experience of Patients Treated With Idecabtagene Vicleucel: A BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma | Annie Hayes | ![]() |
![]() |
|||
P-12 | Cevostamab is efficacious and well tolerated in patients aged 65 and =65 years with relapsed/refractory multiple myeloma (RRMM) | James Bailey | ![]() |
![]() |
|||
P-15 | COMPREHENSIVE COMPARISON OF ALLOGENEIC CAR NK CELLS FOR MM TREATMENT | Elena Maroto Martín | ![]() |
![]() |
|||
P-18 | Optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a Multiple Myeloma model | Michael ODwyer | ![]() |
![]() |
|||
P-21 | 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibody-dependent cell cytotoxicity | Sabrin Tahri | ![]() |
![]() |
|||
P-25 | Investigating the effect of irreversible proteasome inhibitor Carfilzomib in in vivo models of Cardiometabolic Syndrome and early stage HFrEF. Prophylactic role of Metformin. | Evangelos Terpos | ![]() |
![]() |
|||
P-31 | Artificial intelligence analysis of whole-body magnetic resonance imaging of patients with multiple myeloma to find prognostic factors | Hiroyuki Takamatsu | ![]() |
![]() |
|||
P-32 | Lenalidomide maintenance after autologous hematopoetic stem cell transplantation in Hungary from 2016 to 2021 | Viktor Lakatos | ![]() |
![]() |
|||
P-42 | Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | Andrew Yee | ![]() |
![]() |
|||
P-43 | Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias using DW-MRI and Exploratory Bone Biomarkers | Gaurav Agarwal | ![]() |
![]() |
|||
P-46 | Maintenance Therapy Cessation for Patients with Three-Year Sustained MRD Negative Remissions: Initial Results from a Phase II Study | Neha Korde | ![]() |
![]() |
|||
P-47 | ADVANCE multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients | Ola Landgren | ![]() |
![]() |
|||
P-51 | Sustained Bone Marrow and Imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study | Panagiotis Malandrakis | ![]() |
![]() |
|||
P-57 | Studying microRNAs from Extracellular Vesicles as potential biomarkers in liquid biopsies of Multiple Myeloma patients | Rui Bergantim | ![]() |
![]() |
|||
P-58 | Identifying microRNAs as potential biomarkers of drug resistance in Multiple Myeloma patients: proof-of-concept study | Rui Bergantim | ![]() |
![]() |
|||
P-62 | MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course | Cathelijne Fokkema | ![]() |
![]() |
|||
P-64 | Evaluation of single nucleotide variants of CDKN1A, TP53BP, and XRCC1 genes in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with treatment response. | David Garrido | ![]() |
![]() |
|||
P-65 | Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo | Sarah Gooding | ![]() |
![]() |
|||
P-82 | Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma | Madelon de Jong | ![]() |
![]() |
|||
P-91 | Thrombocytopenia with coagulation abnormality in multiple myeloma patients treated with proteasome inhibitor and/or immunomodulatory drugs. | Kazuhito Suzuki | ![]() |
![]() |
|||
P-92 | Impaired glutamine/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation. | Nicola Giuliani | ![]() |
![]() |
|||
P-100 | Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma | Arun Wiita | ![]() |
![]() |
|||
P-104 | Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma | Julia Huber | ![]() |
![]() |
|||
P-106 | Overcoming IMiDs-Resistance in Multiple Myeloma by Targeting MAP4K2 | Shirong Li | ![]() |
![]() |
|||
P-109 | ER-phagic Control of Lipid Metabolism Supports Multiple Myeloma Cell Survival | SIMONE CENCI | ![]() |
![]() |
|||
P-110 | Activity and tolerability of lenalidomide (LLD) is enhanced following low-dose continuous percutaneous delivery compared to once daily dosing in an NCIH929 MM Xenograft model in SCID mice | Jamie Oliver | ![]() |
![]() |
|||
P-111 | Targeting the Mitochondrial Protease ClpP Unveils Novel Vulnerabilities in Multiple Myeloma | SIMONE CENCI | ![]() |
![]() |
|||
P-112 | Anti-BCMA therapy in multiple myeloma. A single-center experience. | Borja Puertas Martínez | ![]() |
![]() |
|||
P-117 | High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma | Philip Weir | ![]() |
![]() |
|||
P-122 | Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma: A Population Based Study | Samer Al Hadidi | ![]() |
![]() |
|||
P-125 | Multiple myeloma in Reunion Island : a descriptive and pronostic study on newly diagnosed patients between 2015 and 2019. | Romain Chane-Teng | ![]() |
![]() |
|||
P-140 | Outreach and Satellite Transplant Clinics Increase Multiple Myeloma (MM) Transplant Referrals and Specifically Transplant Referrals of African American Patients | Anand Jillella | ![]() |
![]() |
|||
P-141 | Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant | Marcella Kaddoura | ![]() |
![]() |
|||
P-143 | SLIM CRAB Criteria revisited: A meta-analysis of studies on biomarker defined early multiple myeloma | Heinz Ludwig | ![]() |
![]() |
|||
P-145 | The clinical significance of a MGUS Tumor Board | Sandy Mazzoni | ![]() |
![]() |
|||
P-146 | Screening Technique for M-proteins in Acetonitrile Precipitates of Serum using MALDI-TOF Mass Spectrometry: A Comparison with Serum Immunofixation Electrophoresis and Serum Free Light Chain Assay | Nikita Mehra | ![]() |
![]() |
|||
P-148 | Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents | Ioannis Ntanasis-Stathopoulos | ![]() |
![]() |
|||
P-149 | Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study | massimo offidani | ![]() |
![]() |
|||
P-150 | Identification of misclassified multiple myeloma patient risk subgroups with a novel biological disease stratifier | Afsaneh Panahi | ![]() |
![]() |
|||
P-151 | Primary Plasma cell Leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group. | Camila Peña | ![]() |
![]() |
|||
P-152 | Prevalence of Monoclonal Gammopathies in adult Uruguayan population | Lucia Pérez Baliero | ![]() |
![]() |
|||
P-153 | Impact of t(11;14) in multiple myeloma on response to treatment and survival. | Borja Puertas Martínez | ![]() |
![]() |
|||
P-156 | Evaluation of SAVED and IMPEDE-VTE Scoring Systems for Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma | Christopher Sandifer | ![]() |
![]() |
|||
P-157 | Carfilzomib (CFZ) resistance is associated with significant deregulation of the BH3 family proteins in multiple myeloma (MM) | Anja Schneller | ![]() |
![]() |
|||
P-158 | End-of-life treatment and treatment costs of multiple myeloma patients in a real-world setting: a retrospective analysis of 91 patients from diagnosis to death | Maarten Seefat | ![]() |
![]() |
|||
P-161 | Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a single-center, prospective study | Vassiliki Spiliopoulou | ![]() |
![]() |
|||
P-163 | MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA: THE MYLORD STUDY FROM THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS) | Oana Mihailescu | ![]() |
![]() |
|||
P-167 | Comparison of frontline treatment regimens in Waldenstr?m Macroglobulinemia a multi-centre Asian cohort | Jing Yuan | ![]() |
![]() |
|||
P-178 | A Pilot Plant Based Dietary Intervention in MGUS And SMM is Feasible and Associated with Reduction in Insulin and Leptin Levels | Urvi Shah | ![]() |
![]() |
|||
P-179 | Comorbidities associated with Monoclonal Gammopathy of Undetermined Significance, Its Subtypes, and Risk Factors | Lawanya Singh | ![]() |
![]() |
|||
P-183 | Outcomes in Respiratory Tract Infections in Hospitalized Multiple Myeloma Patients with Asthma and Chronic Obstructive Pulmonary Disease | Kuldeepsinh Atodaria | ![]() |
![]() |
|||
P-188 | Moving from Research Priorities to Clinical Research: Implementing the Results of a Priority Setting Partnership on Multiple Myeloma | Samantha Fowler | ![]() |
![]() |
|||
P-190 | Bone Remineralization of Lytic Lesions in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, Dexamethasone /- Daratumumab Induction Regimen | Carlyn Tan | ![]() |
![]() |
|||
P-191 | The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review | Hira Mian | ![]() |
![]() |
|||
P-192 | Patient Reported Outcome & Family Reported Outcome and The Most Correlated Clinical Measures Over One Year of Follow-Up | Kareem Midlig | ![]() |
![]() |
|||
P-197 | A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. Carinae study | Gonzalez-Pardo Miriam | ![]() |
![]() |
|||
P-210 | IMPACT OF PRE-TRANSPLANT DISEASE STATUS AND POST-TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT | Vinay Edlukudige Keshava | ![]() |
![]() |
|||
P-213 | Efficacy and Safety of Bortezomib in Once Weekly vs. Twice Weekly Dosing in the Treatment of Multiple Myeloma | Kwan-Keat Ang | ![]() |
![]() |
|||
P-215 | D-VTd as induction therapy in newly diagnosed multiple myeloma (NDMM) patients who are candidates for transplantation: A Real-Life Experience in a single center | Carmen Martínez Chamorro | ![]() |
![]() |
|||
P-218 | Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and Related Diseases Registries. | Justin Ng | ![]() |
![]() |
|||
P-219 | Daratumumab (DARA) lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN | Mary Angelozzi | ![]() |
![]() |
|||
P-222 | A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients | Raija Silvennoinen | ![]() |
![]() |
|||
P-242 | Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) patients with del17p and other high-risk abnormalities (A retrospective single-center study) | HAMID EHSAN | ![]() |
![]() |
|||
P-247 | Addressing the Knowledge Gap to Optimize Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma | Elizabeth Heller | ![]() |
![]() |
|||
P-249 | Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis | Sachin Patel | ![]() |
![]() |
|||
P-255 | Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context: Interim Analysis of the Retrospective IMAGE Study | Mackenzie Baciuska | ![]() |
![]() |
|||
P-258 | Real-world Experience With Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis | Mackenzie Baciuska | ![]() |
![]() |
|||
P-260 | Daratumumab (DARA) Plus Bortezomib and Dexamethasone (D-Vd) or Lenalidomide and Dexamethasone (D-Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analyses of CASTOR and POLLUX | Nicole Triolo | ![]() |
![]() |
|||
P-266 | Favorable Outcomes of 3-weekly Daratumumab-based Regimens in Relapsed/Refractory Multiple Myeloma: Impact of MRD, Rapid Doubling Time, LDH, Triplets and Quadruplets | Cheong Ngai | ![]() |
![]() |
|||
P-267 | Subcutaneous Isatuximab Administration by An On-Body Delivery System in Combination with Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Interim Phase 1b Study Results | Vasudha Chachra | ![]() |
![]() |
|||
P-270 | GO41036: A Phase Ia/Ib open-label, multicenter study evaluating the safety and pharmacokinetics of tiragolumab in combination with atezolizumab and daratumumab in patients with R/R MM | James Bailey | ![]() |
![]() |
|||
P-275 | Bendamustine therapy for advanced relapsed/refractory multiple myeloma | Magen Hila | ![]() |
![]() |
|||
P-277 | Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma | Remi TILMONT | ![]() |
![]() |
|||
P-278 | Post-Authorization Safety of Lenalidomide Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma in Turkey | Daniel Daniel | ![]() |
![]() |
|||
P-283 | TRIATLON - TRIple CLAss exposed/refractory MultipLe MyelOma PatieNts: A real world analysis (RWA) from the Austrian Myeloma Registry (AMR) | Wolfgang Willenbacher | ![]() |
![]() |
|||
P-284 | Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) | MUKUL RASTOGI | ![]() |
![]() |
25-27 August, Los Angeles
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|